SMSPHARMA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
SMS Pharmaceuticals Increases Holding In Sms Peptides To 99.98%
June 27 (Reuters) - SMS Pharmaceuticals Ltd SMSP.NS:
SMS PHARMACEUTICALS LTD - INCREASES HOLDING IN SMS PEPTIDES TO 99.98%
SMS PHARMACEUTICALS LTD - COST OF ACQUISITION 30 MILLION RUPEES
Source text: ID:nBSE32TlBn
Further company coverage: SMSP.NS
(([email protected];))
June 27 (Reuters) - SMS Pharmaceuticals Ltd SMSP.NS:
SMS PHARMACEUTICALS LTD - INCREASES HOLDING IN SMS PEPTIDES TO 99.98%
SMS PHARMACEUTICALS LTD - COST OF ACQUISITION 30 MILLION RUPEES
Source text: ID:nBSE32TlBn
Further company coverage: SMSP.NS
(([email protected];))
India's SMS Pharmaceuticals jumps after FDA clears facility
** Shares of SMS Pharmaceuticals SMSP.NS jumps 5.2% to 252 rupees, on track for third straight session of gains
** Co says U.S. FDA concluded an inspection at its Gagillapur facility in Telangana state with no observations
** More than 300,000 shares traded, 3.1x its 30-day moving avg
** YTD, stock up 0.10%
(Reporting by Yagnoseni Das in Bengaluru)
(([email protected];))
** Shares of SMS Pharmaceuticals SMSP.NS jumps 5.2% to 252 rupees, on track for third straight session of gains
** Co says U.S. FDA concluded an inspection at its Gagillapur facility in Telangana state with no observations
** More than 300,000 shares traded, 3.1x its 30-day moving avg
** YTD, stock up 0.10%
(Reporting by Yagnoseni Das in Bengaluru)
(([email protected];))
SMS Pharmaceuticals Completes USFDA Inspection At Central Laboratory Analytical Services
June 25 (Reuters) - SMS Pharmaceuticals Ltd SMSP.NS:
COMPLETES USFDA INSPECTION AT CENTRAL LABORATORY ANALYTICAL SERVICES
USFDA INSPECTION CONCLUDES WITH ZERO FORM 483 OBSERVATIONS
Source text: ID:nNSEbttpLK
Further company coverage: SMSP.NS
(([email protected];;))
June 25 (Reuters) - SMS Pharmaceuticals Ltd SMSP.NS:
COMPLETES USFDA INSPECTION AT CENTRAL LABORATORY ANALYTICAL SERVICES
USFDA INSPECTION CONCLUDES WITH ZERO FORM 483 OBSERVATIONS
Source text: ID:nNSEbttpLK
Further company coverage: SMSP.NS
(([email protected];;))
SMS Pharmaceuticals Receives EDQM Certification To Supply Ibuprofen In Europe
Oct 1 (Reuters) - SMS Pharmaceuticals Ltd SMSP.NS:
RECEIVES EDQM CERTIFICATION TO SUPPLY IBUPROFEN IN EUROPE
Source text for Eikon: ID:nNSE14Q7HP
Further company coverage: SMSP.NS
(([email protected];;))
Oct 1 (Reuters) - SMS Pharmaceuticals Ltd SMSP.NS:
RECEIVES EDQM CERTIFICATION TO SUPPLY IBUPROFEN IN EUROPE
Source text for Eikon: ID:nNSE14Q7HP
Further company coverage: SMSP.NS
(([email protected];;))
SMS Pharmaceuticals June-Quarter Consol Net PAT 163.7 Mln Rupees
Aug 5 (Reuters) - SMS Pharmaceuticals Ltd SMSP.NS:
SMS PHARMACEUTICALS JUNE-QUARTER CONSOL NET PAT 163.7 MILLION RUPEES
SMS PHARMACEUTICALS JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.64 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: SMSP.NS
(([email protected];))
Aug 5 (Reuters) - SMS Pharmaceuticals Ltd SMSP.NS:
SMS PHARMACEUTICALS JUNE-QUARTER CONSOL NET PAT 163.7 MILLION RUPEES
SMS PHARMACEUTICALS JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.64 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: SMSP.NS
(([email protected];))
SMS Pharmaceuticals Dec-Quarter Consol Net Profit Rises
Feb 8 (Reuters) - SMS Pharmaceuticals Ltd SMSP.NS:
DEC-QUARTER CONSOL NET PROFIT 122.9 MILLION RUPEES VERSUS 52.8 MILLION RUPEES
DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 1.61 BILLION RUPEES VERSUS 1.49 BILLION RUPEES
APPROVED RAISING OF FUNDS THROUGH ISSUE OF CONVERTIBLE EQUITY WARRANTS UP TO 1.14 BILLION RUPEES
Source text for Eikon: ID:nBSE77lJkx
Further company coverage: SMSP.NS
(([email protected];))
Feb 8 (Reuters) - SMS Pharmaceuticals Ltd SMSP.NS:
DEC-QUARTER CONSOL NET PROFIT 122.9 MILLION RUPEES VERSUS 52.8 MILLION RUPEES
DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 1.61 BILLION RUPEES VERSUS 1.49 BILLION RUPEES
APPROVED RAISING OF FUNDS THROUGH ISSUE OF CONVERTIBLE EQUITY WARRANTS UP TO 1.14 BILLION RUPEES
Source text for Eikon: ID:nBSE77lJkx
Further company coverage: SMSP.NS
(([email protected];))
India's SMS Pharmaceuticals Sept-Quarter Consol Net Profit Rises
Nov 8 (Reuters) - SMS Pharmaceuticals Ltd SMSP.NS:
INDIA'S SMS PHARMACEUTICALS SEPT-QUARTER CONSOL NET PROFIT 120.5 MILLION RUPEES VERSUS PROFIT 7.3 MILLION RUPEES
SMS PHARMACEUTICALS LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.67 BILLION RUPEES VERSUS 1.59 BILLION RUPEES
Source text for Eikon: ID:nBSE5NLS2n
Further company coverage: SMSP.NS
(([email protected];))
Nov 8 (Reuters) - SMS Pharmaceuticals Ltd SMSP.NS:
INDIA'S SMS PHARMACEUTICALS SEPT-QUARTER CONSOL NET PROFIT 120.5 MILLION RUPEES VERSUS PROFIT 7.3 MILLION RUPEES
SMS PHARMACEUTICALS LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.67 BILLION RUPEES VERSUS 1.59 BILLION RUPEES
Source text for Eikon: ID:nBSE5NLS2n
Further company coverage: SMSP.NS
(([email protected];))
India's SMS Pharmaceuticals March-Quarter Consol Net PAT falls
May 24 (Reuters) - SMS Pharmaceuticals Ltd SMSP.NS:
INDIA'S SMS PHARMACEUTICALS LTD MARCH-QUARTER CONSOL NET PAT 80.7 MILLION RUPEES VERSUS PROFIT 89 MILLION RUPEES
SMS PHARMACEUTICALS LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.49 BILLION RUPEES VERSUS 609.2 MILLION RUPEES
Source text for Eikon: ID:nBSEbTmNmR
Further company coverage: SMSP.NS
(([email protected];))
May 24 (Reuters) - SMS Pharmaceuticals Ltd SMSP.NS:
INDIA'S SMS PHARMACEUTICALS LTD MARCH-QUARTER CONSOL NET PAT 80.7 MILLION RUPEES VERSUS PROFIT 89 MILLION RUPEES
SMS PHARMACEUTICALS LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.49 BILLION RUPEES VERSUS 609.2 MILLION RUPEES
Source text for Eikon: ID:nBSEbTmNmR
Further company coverage: SMSP.NS
(([email protected];))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Split
Dividend
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does SMS Pharmaceuticals do?
SMS Pharmaceuticals Ltd is a leading Indian pharmaceutical manufacturer with state-of-the-art facilities meeting international standards. The company received export house status in 1997-98 and serves a growing global and local customer base.
Who are the competitors of SMS Pharmaceuticals?
SMS Pharmaceuticals major competitors are Bajaj Healthcare, Hester Biosciences, IOL Chem & Pharma, Solara Active Pharma, Themis Medicare, Morepen Laboratories, Kopran. Market Cap of SMS Pharmaceuticals is ₹2,204 Crs. While the median market cap of its peers are ₹1,642 Crs.
Is SMS Pharmaceuticals financially stable compared to its competitors?
SMS Pharmaceuticals seems to be less financially stable compared to its competitors. Altman Z score of SMS Pharmaceuticals is 4.4 and is ranked 4 out of its 8 competitors.
Does SMS Pharmaceuticals pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. SMS Pharmaceuticals latest dividend payout ratio is 6.8% and 3yr average dividend payout ratio is 5.44%
How has SMS Pharmaceuticals allocated its funds?
Companies resources are allocated to majorly unproductive assets like Accounts Receivable
How strong is SMS Pharmaceuticals balance sheet?
Balance sheet of SMS Pharmaceuticals is strong. But short term working capital might become an issue for this company.
Is the profitablity of SMS Pharmaceuticals improving?
Yes, profit is increasing. The profit of SMS Pharmaceuticals is ₹67.4 Crs for TTM, ₹49.83 Crs for Mar 2024 and -₹7.06 Crs for Mar 2023.
Is the debt of SMS Pharmaceuticals increasing or decreasing?
Yes, The net debt of SMS Pharmaceuticals is increasing. Latest net debt of SMS Pharmaceuticals is ₹269 Crs as of Mar-25. This is greater than Mar-24 when it was ₹208 Crs.
Is SMS Pharmaceuticals stock expensive?
Yes, SMS Pharmaceuticals is expensive. Latest PE of SMS Pharmaceuticals is 31.88, while 3 year average PE is 24.32. Also latest EV/EBITDA of SMS Pharmaceuticals is 17.79 while 3yr average is 17.56.
Has the share price of SMS Pharmaceuticals grown faster than its competition?
SMS Pharmaceuticals has given better returns compared to its competitors. SMS Pharmaceuticals has grown at ~19.5% over the last 7yrs while peers have grown at a median rate of 19.09%
Is the promoter bullish about SMS Pharmaceuticals?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 66.26% and last quarter promoter holding is 64.67%.
Are mutual funds buying/selling SMS Pharmaceuticals?
The mutual fund holding of SMS Pharmaceuticals is decreasing. The current mutual fund holding in SMS Pharmaceuticals is 2.43% while previous quarter holding is 2.55%.